Literature DB >> 22393537

Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.

Lukas T Jeker1, Hélène Bour-Jordan, Jeffrey A Bluestone.   

Abstract

Type 1 Diabetes (T1D), also called juvenile diabetes because of its classically early onset, is considered an autoimmune disease targeting the insulin-producing β cells in the pancreatic islets of Langerhans. T1D reflects a loss of tolerance to tissue self-antigens caused by defects in both central tolerance, which aims at eliminating potentially autoreactive lymphocytes developing in the thymus, and peripheral tolerance, which normally controls autoreactive T cells that escaped the thymus. Like in other autoimmune diseases, the mechanisms leading to T1D are multifactorial and depend on a complex combination of genetic, epigenetic, molecular, and cellular elements that result in the breakdown of peripheral tolerance. In this article, we discuss the contribution of these factors in the development of the autoimmune response targeting pancreatic islets in T1D and the therapeutic strategies currently being explored to correct these defects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22393537      PMCID: PMC3282496          DOI: 10.1101/cshperspect.a007807

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  191 in total

1.  Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

Authors:  Nicole A Sherry; Wei Chen; Jake A Kushner; Mariela Glandt; Qizhi Tang; Sue Tsai; Pere Santamaria; Jeffrey A Bluestone; Anne-Marie B Brillantes; Kevan C Herold
Journal:  Endocrinology       Date:  2007-08-02       Impact factor: 4.736

2.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

4.  Regulatory T cells: stability revisited.

Authors:  Samantha L Bailey-Bucktrout; Jeffrey A Bluestone
Journal:  Trends Immunol       Date:  2011-05-27       Impact factor: 16.687

5.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

6.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Authors:  Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell
Journal:  Lancet       Date:  2008-09-22       Impact factor: 79.321

7.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

8.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Authors:  Li Wen; Ruth E Ley; Pavel Yu Volchkov; Peter B Stranges; Lia Avanesyan; Austin C Stonebraker; Changyun Hu; F Susan Wong; Gregory L Szot; Jeffrey A Bluestone; Jeffrey I Gordon; Alexander V Chervonsky
Journal:  Nature       Date:  2008-09-21       Impact factor: 49.962

9.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

10.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

View more
  38 in total

1.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease.

Authors:  Trevor D Burt
Journal:  Am J Reprod Immunol       Date:  2013-02-25       Impact factor: 3.886

3.  TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions.

Authors:  Pradeep B J Reddy; Taylor H Schreiber; Naveen K Rajasagi; Amol Suryawanshi; Sachin Mulik; Tamara Veiga-Parga; Toshiro Niki; Mitsuomi Hirashima; Eckhard R Podack; Barry T Rouse
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

4.  Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro.

Authors:  Lindsay C Davies; Jessica J Alm; Nina Heldring; Guido Moll; Caroline Gavin; Ioannis Batsis; Hong Qian; Mikael Sigvardsson; Bo Nilsson; Lauri E Kyllonen; Kaija T Salmela; Per-Ola Carlsson; Olle Korsgren; Katarina Le Blanc
Journal:  Stem Cells Transl Med       Date:  2016-07-13       Impact factor: 6.940

5.  Congenic mapping identifies a novel Idd9 subregion regulating type 1 diabetes in NOD mice.

Authors:  Bixuan Lin; Ashley E Ciecko; Erin MacKinney; David V Serreze; Yi-Guang Chen
Journal:  Immunogenetics       Date:  2016-10-28       Impact factor: 2.846

Review 6.  B cells in type 1 diabetes mellitus and diabetic kidney disease.

Authors:  Mia J Smith; Kimber M Simmons; John C Cambier
Journal:  Nat Rev Nephrol       Date:  2017-10-17       Impact factor: 28.314

7.  DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes.

Authors:  Jeffrey D Price; Chie Hotta-Iwamura; Yongge Zhao; Nicole M Beauchamp; Kristin V Tarbell
Journal:  Diabetes       Date:  2015-06-12       Impact factor: 9.461

8.  A Hypermorphic Nfkbid Allele Contributes to Impaired Thymic Deletion of Autoreactive Diabetogenic CD8+ T Cells in NOD Mice.

Authors:  Maximiliano Presa; Jeremy J Racine; Jennifer R Dwyer; Deanna J Lamont; Jeremy J Ratiu; Vishal Kumar Sarsani; Yi-Guang Chen; Aron Geurts; Ingo Schmitz; Timothy Stearns; Jennifer Allocco; Harold D Chapman; David V Serreze
Journal:  J Immunol       Date:  2018-08-20       Impact factor: 5.422

Review 9.  Endotypes in T1D: B lymphocytes and early onset.

Authors:  Mia J Smith; John C Cambier; Peter A Gottlieb
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-08       Impact factor: 3.243

Review 10.  Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials.

Authors:  Hilary R Thomas; Stephen E Gitelman
Journal:  Pediatr Diabetes       Date:  2013-06-17       Impact factor: 4.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.